Tag: Li Tao
Han Kun, Zhong Lun act on Sino Biopharm’s USD950m LaNova buy
Han Kun and Zhong Lun advised on Sino Biopharm’s USD950m acquisition of cancer drugmaker LaNova Medicines
Han Kun and Zhong Lun advised on Sino Biopharm’s USD950m acquisition of cancer drugmaker LaNova Medicines
For Marco Chung, group head of legal at CITIC Securities International, the choice for arbitration seat in China-related disputes is clear